Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCritical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Vascular Health and Risk Management, 11/03/09
Saito S – Pitavastatin is a potent HMG–CoA reductase inhibitor and efficient hepatocyte low–density lipoprotein cholesterol (LDL–C) receptor inducer, producing robust reduction of the serum LDL–C levels, even at a low dose. Pitavastatin and its lactone form are minimally metabolized by CYP enzymes, and are therefore associated with minimal drug–drug interactions (DDIs). Pitavastatin 2 to 4 mg has potent LDL–C–reducing activity, equivalent to that of atorvastatin 10 to 20 mg; several clinical trials have revealed consistently superior high–density lipoprotein cholesterol (HDL–C) elevating activity of pitavastatin than that of atorvastatin. Pitavastatin–induced HDL–C elevation has been shown to be sustained, even incremental, in long–term clinical trials. Pitavastatin was as well–tolerated as atorvastatin or simvastatin in double–blind randomized clinical trials. Two–year long–term safety and effectiveness of pitavastain has been confirmed in a large–scale, prospective post–marketing surveillance. In addition to control of LDL–C, adequate control of triglyceride (TG) and HDL–C, hypertension and hyperglycemia is also necessary in metabolic syndrome patients.
Related Articles
Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence
Current Medical Research and Opinion, 10/05/09
Relevance Score: 43%
Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity
Journal of Molecular and Cellular Cardiology, 10/20/09
Relevance Score: 42%
Corneal Arcus and Cardiovascular Risk Factors in Middle-Aged Subjects in Taiwan
The American Journal of the Medical Sciences, 10/14/09
Relevance Score: 42%
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
Lipids in Health and Disease, 10/13/09
Relevance Score: 42%
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia
Current Medical Research and Opinion, 10/02/09
Relevance Score: 42%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Beta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Sponsor
Article Search
Sponsor